Receptor News and Research

RSS

ARQ 197 demonstrates 66% improvement in median PFS in patients with advanced NSCLC

ArQule, Inc. today announced that ARQ 197, when used in combination with erlotinib, demonstrated a 66% improvement in median Progression-Free Survival in patients with advanced, refractory non-small cell lung cancer.

31 Mar 2010

USPTO issues Notice of Allowance for menadione to prevent skin rash in patients taking EGFR inhibitors

Hana Biosciences, a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for the use of menadione to prevent and treat skin rash in patients taking biologic and small molecule epidermal growth factor receptor inhibitors, such as Erbitux® and Tarceva®, for anti-cancer therapy.

31 Mar 2010

NeurOp and Bristol-Myers Squibb announce drug discovery collaboration

NeurOp Corporation today announced a collaboration with Bristol-Myers Squibb Company (NYSE: BMY) focused upon the development of NeurOp's proprietary small molecules for use in the treatment of major depression and other central nervous system disorders.

31 Mar 2010

Study indicates estrogenic drug could help treat schizophrenia

An estrogenic drug that influences neurotransmitter and neuronal systems in the brain is showing promise as an effective therapy for women who suffer from schizophrenia.

31 Mar 2010

Ikaria Holdings acquires NDA and IND application for LUCASSIN drug

Ikaria Holdings, Inc. announced today that it has acquired the New Drug Application (NDA) and the Investigational New Drug (IND) application to LUCASSIN® (terlipressin for injection) from Orphan Therapeutics, assuming all future development and ownership of the drug in North America and Australia.

31 Mar 2010

Two Phase I studies of Stedivaze demonstrate safety in patients with asthma and COPD

Clinical Data, Inc., today announced results from two Phase I studies of Stedivaze™ (apadenoson), which demonstrated that Stedivaze was safe and well tolerated in patients with asthma and chronic obstructive pulmonary disease (COPD). Stedivaze is a potent and highly selective agonist of the adenosine A2A receptor subtype in development as a pharmacologic stress agent for myocardial perfusion imaging (MPI).

30 Mar 2010

Study: Hormone replacement in joint fluid might be beneficial in treating osteoarthritis

German researchers determined that concentrations of the sex hormones, testosterone in men and estrogen in women, may have a positive effect on the regenerative potential of cartilage tissue. The study suggests hormone replacement in the joint fluid of men and women might be beneficial in treating late stages of human osteoarthritis by regenerating damaged tissue.

30 Mar 2010

Conference on the actions of Vitamin D on human health

An important conference on the actions of Vitamin D on human health is being hosted by Barts and The London Medical School and the MRC Asthma UK Centre in Allergic Mechanisms of Asthma.

30 Mar 2010

Ligand Pharmaceuticals' LGD-4033 SARM Phase I study data featured at 14th endocrinology congress

Ligand Pharmaceuticals Incorporated today announced that data from a Phase I study with its selective androgen receptor modulator (SARM) LGD-4033 was featured today in a poster presentation at the 14th International Congress of Endocrinology in Kyoto, Japan. This Phase I clinical trial was the first study in humans of LGD-4033, and evaluated the safety, tolerability and pharmacokinetic profiles of the molecule in a single escalating dose, double blind, placebo-controlled study in 48 healthy volunteers.

29 Mar 2010

Erbitux can now be used in Japan as 1st-line treatment for mCRC: Merck Serono

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that Erbitux® (cetuximab) can now be used in Japan in combination with chemotherapy in the 1st-line treatment for patients with epidermal growth factor receptor -expressing, curatively unresectable (inoperable), advanced or recurrent colorectal cancer carrying the KRAS wildtype gene.

29 Mar 2010

Study provides new clues to obesity epidemic

In a newly published study, scientists from The Scripps Research Institute have shown for the first time that the same molecular mechanisms that drive people into drug addiction are behind the compulsion to overeat, pushing people into obesity.

29 Mar 2010

Study: Automatic reporting of estimated GFR may result in unnecessary referrals by physicians

With a concern that the automatic reporting of estimated glomerular filtration rate (the flow rate of filtered fluid through the kidney, which is used to define the stage and severity of chronic kidney disease) may result in unnecessary referrals by physicians, new research indicates that automated laboratory reporting was associated with a significant increase in first-time visits to a kidney specialist, particularly among those at increased risk of late detection of kidney disease (such as older or female patients), according to a study in the March 24/31 issue of JAMA.

27 Mar 2010

Presence of PARP protein in tumours can help predict their response to chemotherapy

The presence of the protein poly polymerase in tumours can help predict their response to chemotherapy, a German scientist will tell the seventh European Breast Cancer Conference in Barcelona tomorrow (Saturday 27 March).

27 Mar 2010

Studies shed light on treatment options for women carrying BRCA1 and BRCA2 genetic mutations

Two studies to be presented at the seventh European Breast Cancer Conference (EBCC7) in Barcelona today (Friday) and tomorrow (Saturday), shed light on the treatment options facing women carrying the BRCA1 and BRCA2 genetic mutations which predispose them to breast cancer.

27 Mar 2010

Fundamental step in immune system development discovered

Researchers at National Jewish Health have discovered a fundamental step in the development of the immune system, one that allows B cells to mature and fight disease by producing effective antibodies. Immunologist Roberta Pelanda, PhD, and her colleagues have demonstrated that immature B cells in the bone marrow must receive a positive signal before they can migrate to the spleen where they mature and are activated. In the March 15, 2010 issue of The Journal of Experimental Medicine, the researchers also reported that a protein known as Erk helps deliver that positive signal.

26 Mar 2010

Survival improving in patients with HER2 positive metastatic breast cancer

Barcelona, Spain: Trends indicate that survival is improving in patients with metastatic breast cancer, especially in those patients whose tumours are described as being HER2 (human epidermal growth factor receptor-2) positive, a surgical oncologist will say today at the seventh European Breast Cancer Conference (EBCC7).

26 Mar 2010

Study finds 15-year outcomes of BCT and mastectomy similar

26 Mar 2010

Presence of protein PARP in tumours may help predict response to chemotherapy

The presence of the protein poly (ADP-ribose) polymerase (PARP) in tumours can help predict their response to chemotherapy, a German scientist will tell the seventh European Breast Cancer Conference (EBCC7) in Barcelona tomorrow (Saturday 27 March). Professor Gunter von Minckwitz, from the German Breast Group Forschungs GmBH, Neu-Isenburg, says that, contrary to current belief that PARP is associated with a limited number of tumours, he and his team found for the first time that PARP expression exists across all breast cancer subtypes, and that such tumours were highly sensitive to chemotherapy.

26 Mar 2010

Survival rate is improving in HER2 positive breast cancer patients

Trends indicate that survival is improving in patients with metastatic breast cancer, especially in those patients whose tumours are described as being HER2 (human epidermal growth factor receptor-2) positive, a surgical oncologist will say today (Friday 26 March) at the seventh European Breast Cancer Conference.

26 Mar 2010

Treatment with beta-blockers can help reduce spread of cancer in patients with breast tumours

Treatment with beta-blockers can help reduce the spread of cancer in patients with breast tumours, a researcher will tell the seventh European Breast Cancer Conference in Barcelona today (Friday).

26 Mar 2010

Receptor News and Research

ARQ 197 demonstrates 66% improvement in median PFS in patients with advanced NSCLC

USPTO issues Notice of Allowance for menadione to prevent skin rash in patients taking EGFR inhibitors

NeurOp and Bristol-Myers Squibb announce drug discovery collaboration

Study indicates estrogenic drug could help treat schizophrenia

Ikaria Holdings acquires NDA and IND application for LUCASSIN drug

Two Phase I studies of Stedivaze demonstrate safety in patients with asthma and COPD

Study: Hormone replacement in joint fluid might be beneficial in treating osteoarthritis

Conference on the actions of Vitamin D on human health

Ligand Pharmaceuticals' LGD-4033 SARM Phase I study data featured at 14th endocrinology congress

Erbitux can now be used in Japan as 1st-line treatment for mCRC: Merck Serono

Study provides new clues to obesity epidemic

Study: Automatic reporting of estimated GFR may result in unnecessary referrals by physicians

Presence of PARP protein in tumours can help predict their response to chemotherapy

Studies shed light on treatment options for women carrying BRCA1 and BRCA2 genetic mutations

Fundamental step in immune system development discovered

Survival improving in patients with HER2 positive metastatic breast cancer

Study finds 15-year outcomes of BCT and mastectomy similar

Presence of protein PARP in tumours may help predict response to chemotherapy

Survival rate is improving in HER2 positive breast cancer patients

Treatment with beta-blockers can help reduce spread of cancer in patients with breast tumours

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News